Table 4.
Multivariate Cox regression analyses estimating the influence of cMK2 and nETV1 and clinicopathologic parameters on overall survival (OS) and disease free survival (DFS).
| p-value multivariate | RR | 95% CI | p-value multivariate | RR | 95% CI | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Overall Survival | ||||||||||
| All | ||||||||||
| cMK2 | 0.16 | 1.187 | 0.93 - 1.51 | nETV1 | 0.091 | 0.625 | 0.36 - 1.08 | |||
| UICC Staging | 0.02 | 1.443 | 1.05 - 1.98 | UICC Staging | 0.056 | 1.365 | 0.99 - 1.88 | |||
| (y)pG | 0.07 | 1.201 | 0.98 - 1.47 | (y)pG | 0.09 | 1.187 | 0.97 - 1.45 | |||
| R | 0.81 | 1.044 | 0.73 - 1.48 | R | 0.588 | 1.098 | 0.78 - 1.54 | |||
| Age | <0.001 | 0.981 | 0.97 - 0.99 | Age | <0.001 | 0.979 | 0.97 - 0.99 | |||
| Sex | 0.35 | 0.874 | 0.66 -1.16 | Sex | 0.387 | 0.885 | 0.67 - 1.17 | |||
| NT | 0.04 | 1.352 | 1.01 - 1.81 | NT | 0.005 | 1.491 | 1.13 - 1.97 | |||
| AT | 0.08 | 0.793 | 0.61 - 1.02 | AT | 0.089 | 0.803 | 0.62 - 1.03 | |||
| AC | ||||||||||
| cMK2 | 0.043 | 1.381 | 1.01 - 1.89 | nETV1 | 0.053 | 0.467 | 0.22 - 1.01 | |||
| UICC Staging | 0.087 | 1.460 | 0.95 - 2.25 | UICC Staging | 0.218 | 1.31 | 0.85 - 2.01 | |||
| (y)pG | 0.058 | 1.324 | 0.99 - 1.77 | (y)pG | 1.267 | 0.107 | 0.95 - 1.69 | |||
| R | 0.891 | 1.033 | 0.65 - 1.65 | R | 0.487 | 1.179 | 0.74 - 1.88 | |||
| Age | 0.103 | 0.988 | 0.97 - 1.00 | Age | 0.025 | 0.984 | 0.97 - 1.00 | |||
| Sex | 0.769 | 1.062 | 0.71 - 1.57 | Sex | 0.972 | 0.888 | 0.66 - 1.44 | |||
| NT | 0.034 | 1.498 | 1.03 - 2.18 | NT | 1.626 | 0.01 | 1.12 - 2.36 | |||
| AT | 0.341 | 0.848 | 0.60 -1.19 | AT | 0.888 | 0.488 | 0.64 - 1.24 | |||
| SCC | ||||||||||
| cMK2 | 0.336 | 1.238 | 0.80 - 1.91 | nETV1 | 0.628 | 1.228 | 0.54 - 2.82 | |||
| UICC Staging | 0.526 | 1.177 | 0.71 - 1.95 | UICC Staging | 0.283 | 1.334 | 0.788 - 2.26 | |||
| (y)pG | 0.05 | 1.402 | 0.99 - 1.98 | (y)pG | 0.041 | 1.431 | 1.02 - 2.02 | |||
| R | 0.488 | 1.223 | 0.69 - 2.16 | R | 0.476 | 1.225 | 0.70 - 2.14 | |||
| Age | 0.01 | 0.975 | 0.96 - 0.99 | Age | 0.009 | 0.976 | 0.96 - 0.99 | |||
| Sex | 0.06 | 0.671 | 0.44 - 1.02 | Sex | 0.15 | 0.742 | 0.49 - 1.11 | |||
| NT | 0.725 | 1.097 | 0.66 - 1.83 | NT | 0.188 | 1.359 | 0.86 - 2.14 | |||
| AT | 0.016 | 0.599 | 0.39 - 0.91 | AT | 0.011 | 0.584 | 0.39 - 0.89 | |||
| Disease Free Survival | ||||||||||
| All | ||||||||||
| cMK2 | 0.755 | 1.04 | 0.81 - 1.33 | nETV1 | 0.464 | 0.826 | 0.49 - 1.39 | |||
| UICC Staging | 0.071 | 1.34 | 0.98 - 1.84 | UICC Staging | 0.084 | 1.329 | 0.96 - 1.84 | |||
| (y)pG | 0.084 | 1.20 | 0.98 - 1.47 | (y)pG | 0.099 | 1.184 | 0.97 - 1.45 | |||
| R | 0.615 | 1.094 | 0.91 - 1.55 | R | 0.38 | 1.17 | 0.83 - 1.64 | |||
| Age | < 0.001 | 0.98 | 0.97 - 0.99 | Age | <0.001 | 0.979 | 0.97 - 0.99 | |||
| Sex | 0.752 | 0.955 | 0.72 - 1.27 | Sex | 0.945 | 0.99 | 0.75 - 1.31 | |||
| NT | 0.016 | 1.435 | 1.07 - 1.93 | NT | 0.004 | 1.515 | 1.14 - 2.00 | |||
| AT | 0.084 | 0.80 | 0.61 - 1.03 | AT | 0.11 | 0.812 | 0.63 - 1.05 | |||
| AC | ||||||||||
| cMK2 | 0.403 | 1.145 | 0.83 - 1.57 | nETV1 | 0.216 | 0.637 | 0.31 - 1.30 | |||
| UICC Staging | 0.067 | 1.503 | 0.97 - 2.33 | UICC Staging | 0.144 | 1.38 | 0.90 - 2.12 | |||
| (y)pG | 0.092 | 1.282 | 0.96 - 1.71 | (y)pG | 0.138 | 1.244 | 0.93 - 1.66 | |||
| R | 0.82 | 1.056 | 0.66 - 1.70 | R | 0.494 | 1.176 | 0.74 - 1.87 | |||
| Age | 0.02 | 0.983 | 0.97 - 0.99 | Age | 0.006 | 0.981 | 0.97 - 0.99 | |||
| Sex | 0.70 | 1.082 | 0.73 - 1.61 | Sex | 0.858 | 1.036 | 0.70 - 1.53 | |||
| NT | 0.004 | 1.754 | 1.20 - 2.60 | NT | 0.002 | 1.846 | 1.27 - 2.70 | |||
| AT | 0.488 | 0.887 | 0.63 - 1.24 | AT | 0.597 | 0.914 | 0.65 - 1.28 | |||
| SCC | ||||||||||
| cMK2 | 0.297 | 1.267 | 0.81 - 1.98 | nETV1 | 0.406 | 1.406 | 0.63 - 3.14 | |||
| UICC Staging | 0.793 | 0.932 | 0.55 - 1.57 | UICC Staging | 0.649 | 1.135 | 0.66 - 1.96 | |||
| (y)pG | 0.072 | 1.364 | 0.97 - 1.91 | (y)pG | 0.044 | 1.419 | 1.01 - 1.99 | |||
| R | 0.228 | 1.443 | 0.80 - 2.62 | R | 0.17 | 1.506 | 0.84 - 2.70 | |||
| Age | 0.02 | 0.977 | 0.96 - 0.99 | Age | 0.018 | 0.978 | 0.96 - 1.00 | |||
| Sex | 0.101 | 0.70 | 0.45 - 1.07 | Sex | 0.235 | 0.775 | 0.51 - 1.18 | |||
| NT | 0.684 | 0.895 | 0.52 - 1.53 | NT | 0.609 | 1.129 | 0.71 - 1.80 | |||
| AT | 0.004 | 0.53 | 0.34 - 0.82 | AT | 0.004 | 0.533 | 0.35 - 0.82 | |||
RR = relative risk; CI = confidence interval; cMK2 = cytoplasmic (MAPK)-activated protein kinase 2; nETV1 nuclear of Ets variant gene 1; AC = adenocarcinoma; SCC = squamous cell carcinomas; R = resection margin; UICC = Union for International Cancer Control; NT = neoadjuvant therapy; AT = adjuvant therapy